- Donations
- Home
- About Us
- News
- Background
- Trials Advisory Group
- Clinical Trials Supported
- Events
- Clinical Trials & Research
- Clinical Trial Support
- ANZCHOG Biobanking Network
- Women and Children’s Hospital Tumour Bank, SA
- Perth Children's Hospital Tumour Bank, WA
- Queensland Children’s Tumour Bank, QLD
- Monash Children’s Cancer Biobank, VIC
- Children’s Hospital at Westmead Tumour Bank, NSW
- Children's Cancer Institute Tumour Bank, NSW
- Children's Cancer Centre Biobank, VIC
- Cancer Society Tissue Bank, Christchurch NZ
- Te Ira Kāwai (The Auckland Regional Biobank), Auckland NZ
- Clinical Trials
- Research
- ANZCHOG Children’s Cancer Clinical Trials Repository
- Collaborations
- Unsubscribe
- ASM
- Contact
- How You Can Help
- Sitemap
- Terms Of Use
- Members
- Privacy Policy
- The Challenges of Childhood Cancer
Clinical Trials
- CONNECT2108: Phase 2 Study of the MEK inhibitor MEKTOVI® (binimetinib) for the treatment of Progressive/Recurrent Pediatric Adamantinomatous Craniopharyngioma
- BIOMEDE: Biological Medicine for Diffuse Intrinsic Pontine Glioma Eradication
- NORTH Trial: A phase II study of Panobinostat in Paediatric, Adolescent and Young Adults with Solid Tumours including Neuroblastoma, Osteosarcoma, Malignant Rhabdoid Tumour/Atypical Teratoid Rhabdoid Tumours
- AIM BRAIN: Access to Innovative Molecular Diagnostic Profiling for Paediatric Brain Tumours
- rEECur: An international randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma
- EuroNet-PHL-C2: European Network of Paediatric Hodgkin Lymphoma Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents
- FORUM: Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia – For Omitting Radiotherapy in the Under Majority age
- IntReALL HR 2010: International study for treatment of childhood Relapsed high risk ALL (HR-ALL) 2010: A randomized Phase II Study
- LGG-Avastin: A phase II, open-labeled, multi-center, randomized controlled trial of Vinblastine +/- Bevacizumab (Avastin) for the treatment of chemotherapy-naïve children with unresectable or progressive low grade glioma
- Blin-fant Study: A pilot study to test the feasibility, safety and efficacy of the addition of the BiTE antibody Blinatumomab to the Interfant-06 backbone in infants with MLL-rearranged acute lymphoblastic leukemia: A collaborative study of the Interfant network
- MyeChild 01: International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia: Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination with Induction Chemotherapy
- PARC: An international phase I/II study evaluating the safety and activity of Pegylated recombinant human Arginase (BCT-100) in Relapsed/refractory cancers of Children and young adults.
- PRISM: PRecISion Medicine for Children with Cancer
- Pαβlo: Paediatric αβ haploidentical transplantation
- COZMOS: Phase I/Ib trial of Combined 5’azacitidine and carboplatin for recurrent/refractory paediatric brain and solid tumours
- SJ ELiOT: Phase 1 Evaluation of LY2606368, a CHK inhibitor, in combination with cyclophosphamide or gemcitabine for children & adolescents with recurrent medulloblastoma tumours.
- Hypermutant Cancers Trial: A Pilot Study of Nivolumab in Paediatric Patients with Hypermutant Cancers
- FaR-RMS: Frontline and Relapse Study in RhabdomyoSarcoma Study
- TINT: A phase II study of trametinib in paediatric, adolescent and young adult patients with Neurofibromatosis type 1 associated plexiform neurofibromas or progressive optic pathway gliomas.
- MNP2.0: Molecular Neuropathology 2.0
- LINES: European Low and Intermediate Risk Neuroblastoma (Phase III SIOPEN study)
- SIOPEN SCI Registry: Prospective Study Registry of Peripheral Neuroblastic Tumours Presenting with Spinal Canal Involvement
- HR-NBM study: High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
- INFORM2 NivEnt: Phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
- PNOC019/NICHE-HGG: A Pilot Trial of Neoadjuvant Checkpoint Inhibition followed by Combination Adjuvant Checkpoint Inhibition in Children and Young Adults with Recurrent or Progressive High Grade Glioma (HGG)
- ReRAD: A Phase II Canadian Paediatric Brain Tumour Consortium Study of Re – Irradiation as Treatment of Progressive or Recurrent Diffuse Intrinsic Pontine Glioma
- CONNECT 1903: A Pilot and Surgical Study of Larotrectinib for Treatment of Children with Newly-Diagnosed High-Grade Glioma with NTRK Fusion
- Study 10: International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia (AIEOP-BFM ALL 2017)
- INTER-EWING- 1: INTERnational scientific program in clinical research to improve outcomes of newly diagnosed EWING sarcoma – trial 1
- PNOC-022 (DMG-ACT): A Combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas including Diffuse Intrinsic Pontine Gliomas at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression.
- MetMED: Phase III randomized double-blind placebo-controlled trial of metformin for white matter repair and cognitive recovery in paediatric brain tumour patients
- CONNECT1905: Phase 2 Study of Systemic IL-6 Receptor Antagonist ACTEMRA® (tocilizumab) for the treatment of Progressive/Recurrent Pediatric Adamantinomatous Craniopharyngioma
- RAVEN: A phase I/II trial treating relapsed acute lymphoblastic leukemia with venetoclax and navitoclax
- SJiMB21: Phase 2 Study of Molecular and Clinical Risk-Directed Therapy for Infants and Young Children with Newly Diagnosed Medulloblastoma
Posts
- World First: Australian child first in the world to trial new brain cancer treatment
- Former ANZCHOG Chair Peter Downie recognised in Australia Day honours
- The Zero Childhood Cancer Program (ZERO)
expands to include all young Australians with cancer - Funding secured for Interfant-21 study
- An Australian first: Newly accredited diagnostic tool to transform diagnosis of children with brain cancer.
- Acknowledging the achievements of Audrey Evans
- September was Childhood Cancer Awareness Month
- METMED: New clinical trial available for children who have undergone treatment for Medulloblastoma
- COVID-19 Vaccination Guidance for children 6 months and older undergoing cancer treatment and children with non-cancerous blood disorders – UPDATED
- Community partner – Run for Run DIPG
- The Australian Bragg Centre for Proton Therapy and Research National Consumer Advisory Group – Expressions of Interest
- Community partner – Super Max & Bryce
- Community partner event – Adventure Challenge Trek4BrainCancer
- Community partner event – Connor’s Run
- Community partner event – The Better Challenge
- Community partner event – Connor’s Run
- September is Childhood Cancer Awareness Month
- New clinical trial now open for children with deadly brain cancers.
- An insight into paediatric oncology in Papua New Guinea with Dr Gwenda Anga.
- Optimal Care Pathways: new national standards for blood cancer treatment and care
- An insight into paediatric oncology in New Caledonia with Dr Gregory Harvet.
- ANZCHOG would like to congratulate Professor Richard Cohn (AM), who has been recognised in the 2022 Queen’s Birthday Honours list.
- TRIAL UPDATE: A Pilot Study of Nivolumab in Paediatric Patients with Hypermutant Cancers
- COVID-19 Vaccination Guidance for children 5 years and older undergoing cancer treatment and children with non-cancerous blood disorders
- COVID-19 Vaccination Guidance for children 5 years and older undergoing cancer treatment and children with non-cancerous blood disorders
- COVID-19 Vaccination Guidance for children 5 years and older undergoing cancer treatment and children with non-cancerous blood disorders
- COVID-19 School attendance guidance for children undergoing cancer treatment and children with non-cancerous blood disorders – UPDATED
- INTER-EWING-1: A new international trial for Ewing Sarcoma patients
- COVID-19 Vaccination Guidance for children 5 years and older undergoing cancer treatment and children with non-cancerous blood disorders
- COVID-19 School attendance guidance for children undergoing cancer treatment and children with non-cancerous blood disorders
- COVID-19 Vaccination Guidance for children 12 years and older undergoing cancer treatment and children with non-cancerous blood disorders
- MyeChild 01 Milestone: 100 Australian and New Zealand patients
- Spotlight Series – Tanya Alestalo
- Spotlight Series – Robyn Strong
- Spotlight Series – Associate Professor Maria McCarthy
- Spotlight Series – Dr Jennifer Cohen
- Spotlight Series – Dr Raelene Endersby
- Spotlight Series – Hayley Vasileff
- Spotlight Series – Professor Nick Gottardo
- Spotlight Series – Anne Kay
- Spotlight Series – Helen Starosta
- Spotlight Series – Dr Tristan Pettit
- COVID-19 Vaccination Guidance for children 12 years and older undergoing cancer treatment and children with non-cancerous blood disorders
- Spotlight Series – Reg Gayaman
- Spotlight Series – Natalie Bradford
- SAHMRI & Australian Bragg Centre for Proton Therapy and Research Webinars
- FaR-RMS: A new trial now open for children and adults with rhabdomyosarcoma
- CONNECT-1903: A new trial for brain cancer now available in Australia
- PNOC-019/ NICHE-HGG: Now open in Australia
- TiNT Trial: Now open in Australia & New Zealand
- Zero Childhood Cancer Nature Medicine Paper Published
- Running with an AIM
- Launch of the National Strategic Action Plan for Blood Cancer
- New funding to support the NICHE-HGG Trial
- Touched by Childhood Cancer
- COSA Position Statement: Exercise in Cancer Care
- Three ANZCHOG trials awarded funding by Australian Government Clinical Trial Initiatives
- Updated advice for paediatric oncology and BMT patients during the COVID-19 pandemic
- A multicentre study of SARS-CoV-2 infection in children with cancer, immunodeficiency or following stem cell transplant
- TGA – Considerations for the Inclusion of Adolescents in Adult Oncology Clinical Trials
- COVID-19 Guidance for children and young people undergoing cancer treatment
- COVID-19 Guidance and FAQ for children and young people undergoing cancer treatment
- Financial Markets Foundation for Children to Boost Capacity For Brain Cancer Clinical Trials at Australian Paediatric Oncology Centres
- SJ ELiOT opens at Perth Children’s Hospital
- ANZCHOG and The Kids’ Cancer Project in Canberra
- MNP2.0 and AIM BRAIN PROJECT– NEW HOPE FOR CHILDREN WITH BRAIN CANCER
- My Room to support ANZCHOG leukaemia trial
- The Kids’ Cancer Project helping ANZCHOG to open new trials
- New funding to support three ANZCHOG trials
- Australian Brain Cancer Mission to support ANZCHOG
- Carrie’s Beanies announces support for AIM-Brain project